S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 40 of 44

Issue Date	Title / Author(s) / Citation	File
1999-11	Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma Hong, Semie; Wu, Hong Gyun; Chie, Eui Kyu; Bang, Yung-Jue; Heo, Dae Seog; Kim, Kwang Hyun; Sung, Myung Whun; Park, Charn Il International Journal of Radiation Oncology Biology Physics, Vol.45 No.4, pp.901-905	DOI
2004-12	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma Sun, Jong-Mu; Han, Wonshik; Im, Seock-Ah; Kim, Tae-You; Park, In Ae; Noh, Dong-Young; Heo, Dae Seog; Bang, Yung-Jue; Choe, Kuk Jin; Kim, Noe Kyeong Cancer, Vol.101 No.11, pp.2516-2522	DOI
2006-12	Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Lee, Ju-Hee; Park, Jung-Hyun; Jung, Yeonjoo; Kim, Jee-Hyun; Jong, Hyun-Soon; Kim, Tae-You; Bang, Yung-Jue Molecular Cancer Therapeutics, Vol.5 No.12, pp.3085-3095	DOI
2007-11	Negative impact of heat exposure on cosmesis after conservative treatment for breast cancer Chie, Eui Kyu; Kim, Kyubo; Noh, Dong-Young; Choe, Kuk Jin; Kim, Tae-You; Im, Seok-Ah; Bang, Yung-Jue; Ha, Sung W. Tumori, Vol.93 No.6, pp.591-596	DOI
2008-10	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer Rhee, Jiyoung; Han, Sae-Won; Oh, Do-Youn; Kim, Jee Hyun; Im, Seock-Ah; Han, Wonshik; Park, In Ae; Noh, Dong-Young; Bang, Yung-Jue; Kim, Tae-You BMC Cancer, Vol.8, p. 307	view file DOI
2009-04	Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment Moon, H. -G.; Han, W.; Lee, J. W.; Ko, E.; Kim, E. -K.; Yu, J. -H.; Kang, S. Y.; Moon, W. K.; Cho, N.; Park, I. -A.; Oh, D. -Y.; Han, S. -W.; Im, S. -A.; Noh, D. -Y. Annals of Oncology, Vol.20 No.4, pp.636-641	DOI
2009-08	Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma Koh, Y.; Kim, T. M.; Jeon, Y. K.; Kwon, T. -K.; Hah, J. H.; Lee, S. -H.; Kim, D. -W.; Wu, H. -G.; Rhee, C. -S.; Sung, M. -W.; Kim, C. W.; Kim, K. H.; Heo, D. S. Annals of Oncology, Vol.20 No.8, pp.1414-1419	DOI
2009-11	Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and beta III-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival Kang, Chang Hyun; Jang, Bo Gun; Kim, Dong-Wan; Chung, Doo Hyun; Kim, Young Tae; Jheon, Sanghoon; Sung, Sook-Whan; Kim, Joo Hyun Journal of Thoracic Oncology, Vol.4 No.11, pp.1307-1312	DOI
2009-12	Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy Park, Chul-Kee; Lee, Se-Hoon; Han, Jung Ho; Kim, Chae-Yong; Kim, Dong-Wan; Paek, Sun Ha; Kim, Dong Gyu; Heo, Dae Seog; Kim, Il Han; Jung, Hee-Won BMC Cancer, Vol.9, p. 450	view file DOI
2010-02	Prognostic Factors Affecting the Outcome of Salvage Radiotherapy for Isolated Locoregional Recurrence After Mastectomy Kim, Kyubo; Chie, Eui Kyu; Han, Wonshik; Noh, Dong-Young; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue; Ha, Sung W. American Journal of Clinical Oncology, Vol.33 No.1, pp.23-27	DOI
2010-08	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Bang, Yung-Jue; Van Cutsem, Eric; Feyereislova, Andrea; Chung, Hyun C.; Shen, Lin; Sawaki, Akira; Lordick, Florian; Ohtsu, Atsushi; Omuro, Yasushi; Satoh, Taroh; Aprile, Giuseppe; Kulikov, Evgeny; Hill, Julie; Lehle, Michaela; Ruschoff, Josef; Kang, Yoon-Koo The Lancet, Vol.376 No.9742, pp.687-697	DOI
2011-01	High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer Rhee, Jiyoung; Han, Sae-Won; Cha, Yongjun; Ham, Hye Seon; Kim, Hwang-phill; Oh, Do-Youn; Im, Seock-Ah; Park, Jong-Wan; Ro, Jungsil; Lee, Keun Seok; Park, In Hae; Im, Young-Hyuck; Bang, Yung-Jue; Kim, Tae-You Breast Cancer Research and Treatment, Vol.125 No.1, pp.107-114	DOI
2011-05	Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab Chang, Hye Jung; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Jeon, Yoon Kyung; Park, In Ae; Han, Wonshick; Noh, Dong-Young; Bang, Yung-Jue; Kim, Tae-You Japanese Journal of Clinical Oncology, Vol.41 No.5, pp.593-599	DOI
2011-11	Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma Kim, Min A.; Lee, Hyuk-Joon; Yang, Han-Kwang; Bang, Yung-Jue; Kim, Woo Ho Histopathology, Vol.59 No.5, pp.822-831	DOI
2012-01	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Gianni, Luca; Pienkowski, Tadeusz; Im, Young-Hyuck; Roman, Laslo; Tseng, Ling-Ming; Liu, Mei-Ching; Lluch, Ana; Staroslawska, Elzbieta; de la Haba-Rodriguez, Juan; Im, Seock-Ah; Pedrini, Jose Luiz; Poirier, Brigitte; Morandi, Paolo; Semiglazov, Vladimir; Srimuninnimit, Vichien; Bianchi, Giulia; Szado, Tania; Ratnayake, Jayantha; Ross, Graham; Valagussa, Pinuccia The Lancet Oncology, Vol.13 No.1, pp.25-32	DOI
2012-03	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells Kim, Hye Jin; Kim, Hwang-Phill; Yoon, Young-Kwang; Kim, Maeng-Sup; Lee, Gwan-Sun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue Anti-Cancer Drugs, Vol.23 No.3, pp.288-297	DOI
2012-07	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer Han, Sae-Won; Cha, Yongjun; Paquet, Agnes; Huang, Weidong; Weidler, Jodi; Lie, Yolanda; Sherwood, Thomas; Bates, Michael; Haddad, Mojgan; Park, In Hae; Oh, Do-Youn; Lee, Keun Seok; Im, Seock-Ah; Bang, Yung-Jue; Ro, Jungsil; Kim, Tae-You PLoS ONE, Vol.7 No.7, p. e0039943	DOI
2012-08	ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy Kim, Ji-Won; Kim, Jee Hyun; Im, Seock-Ah; Kim, Yu Jung; Han, Hye-Suk; Kim, Jin-Soo; Han, Sae-Won; Jeon, Yoon Kyung; Oh, Do-Youn; Han, Wonshik; Kim, Tae-You; Park, In Ae; Noh, Dong-Young; Bang, Yung-Jue Oncology, Vol.83 No.4, pp.218-227	DOI
2012-09	Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer Bang, Yung-Jue Journal of Clinical Gastroenterology, Vol.46 No.8, pp.637-648	DOI
2012-12	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data Lee, Kytmg-Hun; Keam, Bhumsuk; Im, Seock-Ah; Kim, Tae-Yong; Han, Sae-Won; Oh, Do-Youn; Kim, Jee Hyun; Lee, Se-Hoon; Han, Wonshik; Kim, Dong-Wan; Kim, Tae-You; Park, In Ae; Noh, Dong-Young; Heo, Dae Seog; Bang, Yung-Jue Journal of Breast Cancer, Vol.15 No.4, pp.427-433	view file DOI
2013-03	Predictive markers for neoadjuvant chemotherapy in advanced squamous cell carcinoma of maxillary sinus: Preliminary report Choi, Ik Joon; Kim, Dong-Wan; Kim, Dong-Young; Lee, Chul Hee; Rhee, Chae-Seo Acta Oto-Laryngologica, Vol.133 No.3, pp.291-296	DOI
2013-07	HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer Kim, Ji-Won; Kim, Jee Hyun; Im, Seock-Ah; Kim, Yu Jung; Han, Hye-Suk; Kim, Jin-Soo; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Sae-Won; Jeon, Yoon Kyung; Oh, Do-Youn; Kim, Tae-You; Park, In Ae Cancer Chemotherapy and Pharmacology, Vol.72 No.1, pp.109-115	DOI
2013-10	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer Cortes, J.; Baselga, J.; Im, Y. -H.; Im, S. -A.; Pivot, X.; Ross, G.; Clark, E.; Knott, A.; Swain, S. M. Annals of Oncology, Vol.24 No.10, pp.2630-2635	DOI
2013-11	Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy Kim, Ji-Won; Kim, Jee Hyun; Im, Seock-Ah; Lee, Kyung-Hun; Kim, Jin-Soo; Kim, Tae-Yong; Han, Sae-Won; Jeon, Yoon Kyung; Oh, Do-Youn; Kim, Tae-You; Park, In Ae Cancer Chemotherapy and Pharmacology, Vol.72 No.5, pp.1023-1029	DOI
2014-07	Safety profile of pertuzumab with trastuzumab and docetaxel in patients from asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: Results from the phase III trial CLEOPATRA Swain, Sandra M.; Im, Young-Hyuck; Im, Seock-Ah; Chan, Valorie; Miles, David; Knott, Adam; Clark, Emma; Ross, Graham; Baselga, Jose Oncologist, Vol.19 No.7, pp.693-701	DOI
2014-08	Immunohistochemical Features Associated with Sensitivity to Lapatinib-plus-Capecitabine and Resistance to Trastuzumab in HER2-positive Breast Cancer Cha, Yongjun; Han, Sae-Won; Seol, Hyesil; Oh, Do-Youn; Im, Seock-Ah; Bang, Yung-Jue; Park, In Ae; Han, Wonshik; Noh, Dong-Young; Kim, Tae-You Anticancer Research, Vol.34 No.8, pp.4275-4280
2014-12	HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer Lee, Hee Jin; Seo, An Na; Kim, Eun Joo; Jang, Min Hye; Suh, Koung Jin; Ryu, Han Suk; Kim, Yu Jung; Kim, Jee Hyun; Im, Seock-Ah; Gong, Gyungyub; Jung, Kyung Hae; Park, In Ae; Park, So Yeon American Journal of Clinical Pathology, Vol.142 No.6, pp.755-766	DOI
2015-12	Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer Ahn, Soo Kyung; Lee, Han-Byoel; Han, Wonshik; Moon, Hyeong-Gon; You, Jee Man; Kim, Jisun; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Noh, Dong-Young Annals of Surgical Oncology, Vol.22, pp.S391-S397	DOI
2016-01	Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer Kim, Ji-Won; Kim, Debora K.; Min, Ahrum; Lee, Kyung-Hun; Nam, Hyun-Jin; Kim, Jee Hyun; Kim, Jin-Soo; Kim, Tae-Yong; Im, Seock-Ah; Park, In Ae Journal of Cancer Research and Clinical Oncology, Vol.142 No.1, pp.157-165	DOI
2016-06	Prognostic role of body mass index in advanced small bowel adenocarcinoma patients receiving palliative chemotherapy Lee, Dae-Won; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue Nutrition and Cancer, Vol.68 No.5, pp.750-755	DOI
2016-08	New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer Jin, Min-Sun; Park, In Ae; Kim, Ji Young; Chung, Yul Ri; Im, Seock-Ah; Lee, Kyung-Hun; Moon, Hyeong-Gon; Han, Wonshik; Noh, Dong-Young; Ryu, Han Suk Tumor Biology, Vol.37 No.8, pp.11017-11024	DOI
2017-04	First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors Bang, Y. J.; Giaccone, G.; Im, S. A.; Oh, D. Y.; Bauer, T. M.; Nordstrom, J. L.; Li, H.; Chichili, G. R.; Moore, P. A.; Hong, S.; Stewart, S. J.; Baughman, J. E.; Lechleider, R. J.; Burris, H. A. Annals of Oncology, Vol.28 No.4, pp.855-861	DOI
2017-09	Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics Lee, Jeong Sub; Kim, Se Hyung; Im, Seock-Ah; Kim, Min A.; Han, Joon Koo Korean Journal of Radiology, Vol.18 No.5, pp.809-820	DOI
2017-12	Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study Park, Jin Hyun; Choi, In Sil; Kim, Ki Hwan; Kim, Jin-Soo; Lee, Kyung-Hun; Kim, Tae-Yong; Im, Seock Ah; Kim, Se Hyun; Kim, Yu Jung; Kim, Jee Hyun Journal of Breast Cancer, Vol.20 No.4, pp.368-377	DOI
2018-10	Oncologic safety of gonadotropin-releasing hormone agonist for ovarian function protection during breast cancer chemotherapy Kim, Hee Jeong; Lee, Moo Hyun; Lee, Jeong Eon; Park, Seho; Lee, Eun Sook; Kang, Yong Joon; Shin, Hae Na; Kim, Seung Il; Lee, Jun Ho; Im, Seock Ah; Ahn, Sei Hyun; Lee, Keun Seok; Sohn, Joohyuk; Kim, Seonok; Nam, Seok Jin; Han, Wonshik Clinical Breast Cancer, Vol.18 No.5, pp.e1165-e1172	DOI
2019-03	Central nervous system failure in Korean breast cancer patients with HER2-enriched subtype: Korean radiation oncology group 16-15 multicenter retrospective study Kim, Kyubo; Shin, Kyung Hwan; Kim, Jin Ho; Choi, Doo Ho; Park, Won; Kim, Yong Bae; Kim, Hyun Ju; Kim, Jin Hee; Park, Hyeli; Lee, Sun Young; Kim, Jiyoung; Oh, Do Hoon; Kim, In Ah Journal of Breast Cancer, Vol.22 No.1, pp.120-130	DOI
2019-12	Amenorrhea and menopause in patients with breast cancer after chemotherapy Shin, Jae Jun; Choi, Young Min; Jun, Jong Kwan; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Wonshik; Im, Seock-Ah Journal of Breast Cancer, Vol.22 No.4, pp.624-634	DOI
2020-03	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC Tan, Wan Ling; Chua, Kevin L. M.; Lin, Chia-Chi; Lee, Victor H. F.; Tho, Lye Mun; Chan, Anthony W.; Ho, Gwo Fuang; Reungwetwattana, Thanyanan; Yang, James C.; Kim, Dong-Wan; Soo, Ross A.; Ahn, Yong Chan; Onishi, Hiroshi; Ahn, Myung-Ju; Mok, Tony S. K.; Tan, Daniel S. W.; Yang, Fan Journal of Thoracic Oncology, Vol.15 No.3, pp.324-343	DOI
2020-04	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS Park, Y. H.; Senkus-Konefka, E.; Im, S. -A.; Pentheroudakis, G.; Saji, S.; Gupta, S.; Iwata, H.; Mastura, M. Y.; Dent, R.; Lu, Y. -S.; Yin, Y.; Smruti, B. K.; Toyama, T.; Malwinder, S.; Lee, S. C.; Tseng, L. -M.; Kim, J. H.; Kim, T. -Y.; Suh, K. J.; Cardoso, F.; Yoshino, T.; Douillard, J. -Y. Annals of Oncology, Vol.31 No.4, pp.451-469	DOI
2020-06	Effect of timing of gonadotropin-releasing hormone agonist administration for ovarian protection in patients with breast cancer Shin, Jae Jun; Choi, Young Min; Jun, Jong Kwan; Lee, Kyung-Hun; Kim, Tae-Yong; Han, Wonshik; Im, Seock-Ah Journal of Breast Cancer, Vol.23 No.3, pp.268-278	DOI

1 2